logo
What Are Rope Worms? Are They Even Real?

What Are Rope Worms? Are They Even Real?

Health Line03-06-2025
'Rope worms' may simply be shed pieces of intestinal mucus. Mucus can be more common with certain health conditions, including inflammatory bowel disease and colon cancer.
Multiple types of intestinal parasites can infect human bodies, including tapeworms, pinworms, and hookworms. In recent years, the rope worm has been discussed as another potential intestinal inhabitant.
While some people believe that so-called 'rope worms' are intestinal parasites, the more plausible theory is that these 'worms' are more likely strands of intestinal mucus.
The parasite theory
Belief in rope worms is only a recent development. In 2013, a non-peer-reviewed research paper published by Dr. Alex Volinsky and his colleagues claimed that the rope worm, otherwise known as funis vermes, is a parasite that spends its entire life inside the human body.
Volinsky and his colleagues say that there are five stages of the rope worm life cycle. They claim that there are various methods of extraction for each developmental stage, including salt milk enemas, baking soda enemas, and eucalyptus/lemon juice enemas.
They believe that if these rope worms aren't flushed from the body, they can release toxins that may have negative cognitive effects.
The rope worm myth is often associated with proponents of the medication ivermectin, who believe without proof that it's an effective treatment for COVID-19.
There's no scientific evidence for the existence of these 'rope worms.'
The intestinal lining/mucus buildup theory
The intestinal lining or mucus buildup theory claims that these long rope-like structures are simply shed pieces of intestinal mucus.
Intestinal mucus is produced as a barrier to prevent harmful microorganisms from entering the bloodstream through the intestines. As with all cells in the body, these intestinal barrier cells routinely turn over and shed.
While routine shedding is typical, excessive or altered shedding of intestinal mucus may be a sign of gastrointestinal conditions like inflammatory bowel disease (IBD) or colon cancer.
During enemas and colon hydrotherapy sessions, some people experience a flushing of what's believed to be a buildup of mucus. This buildup of mucus, which is sometimes referred to as mucoid plaque, actually closely resembles what others believe is the 'rope worm.'
There is no definitive scientific proof that mucoid plaque buildup exists. However, there is even less scientific proof for the rope worm's existence as an intestinal parasite.
Perhaps the most critical evidence against the parasite theory is the fact that when the DNA of the 'rope worm' specimen was tested, it consisted of 99% human DNA.
Picture of 'rope worms'
Taking care of your digestive system
It's believed that eating a diet rich in processed foods may contribute to the presence of rope worms or the buildup of mucoid plaque. While there's no scientific proof to support this theory, there's merit behind the idea of maintaining a healthy gut.
Gut health is just as important as heart health, lung health, and the health of any other organ in the body. Even if the literature doesn't prove the existence of rope worms or mucoid plaque, here are some ways you can take care of your digestive system:
Drink plenty of water. Hydration is important for all body cells, including the mucus-producing cells of the intestines. Hydration can also help prevent constipation. Make sure you're keeping up on your water intake throughout the day.
Eat plenty of fruits, vegetables, healthy fats, and whole grains. Fruits, vegetables, and whole grains are full of fiber, which can help keep the digestive tract functioning smoothly. These foods are also good sources of antioxidants, which help to support your gut health.
Keep a consistent sleep schedule. It's no secret that a lack of sleep can have negative effects on the body, including our digestion. Keeping a healthy, consistent sleep schedule and sleeping 7 to 9 hours per night can help support a healthy microbiome.
Practice relaxation techniques. Stress, anxiety, and other strong emotions can influence gut health and your digestion. For example, depression has been linked to symptom flare-ups in patients with IBS. Using relaxation techniques may help reduce the negative effects of stress on your digestion.
Keep an eye on the symptoms of food intolerances. Food allergies and sensitivities can affect anyone, from children to older adults. If you have gastrointestinal symptoms when you eat certain foods, it may be worth a visit to a doctor just to check for food intolerances.
Key takeaways
'Rope worms' are allegedly discovered during enemas and colonics. Little evidence supports the theory that these 'worms' are a newly discovered type of human parasite.
The more likely explanation for the expulsion of these rope-like strands is the shedding of intestinal mucus. However, both theories lack the necessary scientific evidence to definitively say what these 'rope worms' really are.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns

Yahoo

time4 hours ago

  • Yahoo

Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns

Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store